Crysvita Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The global crysvita market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Crysvita is an FDA-approved treatment that supports the body to retain phosphorus and test its effectiveness and safety in adults and children with XLH. In June 2019.

FDA approved crysvita to treat osteoporosis in patients with a rare form of bone marrow transplantation with low phosphate levels and it is known as tumor-induced osteomalacia (TIO), and crysvitainfects patients whose tumors can be surgically removed and it belongs to a group of drugs called monoclonal antibodies, endocrine.

The increase in the prevalence of crysvita disease has created a demand for the development of new drugs for its treatment which in turn drives the global crysvita market growth. According to the estimation of the International Osteoporosis Foundation (IOF), 75 million people in Europe, USA and Japan are affected by osteoporosis. Worldwide, osteoporosis is estimated to affect 200 million women – approximately one-tenth of women aged 60, one-fifth of women aged 70, two-fifths of women aged 80 and two-thirds of women aged 90.

An IOF survey, conducted in 11 countries, showed denial of personal risk by postmenopausal women, lack of dialogue about osteoporosis with their doctor, and restricted access to diagnosis and treatment before the first fracture result in under-diagnosis and under treatment of the disease. Furthermore, the ageing of populations across the globe will be responsible for a major increase in the incidence of osteoporosis in postmenopausal women. The crysvita 20mg tablet is approved by the US FDA for XLH treatment in September 2021 for patients and children six months and older and FGF23-related hypophosphatemia in TIO associated with phosphaturic mesenchymal tumors that can be treated or localized in adults and 2-year-old patients.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape-Azer Scientific, Inc, Genta Environmental Ltd, Global Scientific Inc, Cardinal Health Inc.,and Merck & Co., Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global CrysvitaMarket Report by Segment

By Type

• 10 mg Tablet
• 20 mg Tablet
• 30 mg Tablet

By Application

• Hospitals
• Clinics
• Others